Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19

  • Financial results reflecting strong Cresemba and Zevtera performance and continued focus on expense management
  • Operating profit of CHF 12.8 million and net profit of CHF 9.9 million, including positive one-time effect from the sale of headquarters property
  • Solid cash and investments of approximately CHF 145 million, excluding cash proceeds from July bond transactions for improving debt maturity profile
  • No material COVID-19-related impact on operating performance and key studies for derazantinib and lisavanbulin and limited delay in phase 3 study with Zevtera
  • FY 2020 guidance on revenues and operating expenses confirmed;
    strong year-end cash and investments position expected

Basel, Switzerland, August 11, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the first six months ended June 30, 2020.

David Veitch, Chief Executive Officer, said: “We have achieved significant milestones in a highly volatile and challenging environment in the first half year of 2020. Despite the COVID-19 pandemic, the global in-market sales of our anti-infective brands, Cresemba and Zevtera, continued to show strong growth. We have also seen no material COVID-19-related impact on the key studies for our most advanced oncology drug candidates, derazantinib and lisavanbulin, and expect as previously announced, only a limited delay of potentially up to one quarter in the patient enrolment timelines for our phase 3 study with Zevtera in patients with Staphylococcus aureus bacteremia. Importantly, the U.S. FDA approved the extension to the maximum treatment duration in the study from four to up to six weeks, which will be beneficial for positioning, should the drug be approved, as it would allow for the treatment of more difficult-to-treat infections.”

He added: “We have also taken a major step forward in the optimization of our debt maturity profile, by the successful placement of new senior convertible bonds of approximately CHF 97 million and the repurchase of approximately CHF 47 million of our outstanding convertible bonds. Through this, we extended in an initial step the maturity of about 25 percent of our mid-term debt to 2027. In addition, we sold our headquarters property in preparation to moving to a new location in the Basel area in 2022. Based on both a strong underlying financial performance and the one-time effect from this sale, we are pleased to report an operating profit of approximately CHF 13 million and a net profit of almost CHF 10 million for the first half-year 2020.”

He continued: “We are looking forward to a number of important milestones in our oncology portfolio in the second half of the year and beyond. Following the recently announced completion of patient enrolment into the first cohort of the FIDES-01 derazantinib study in patients with bile duct cancer and FGFR2 gene fusions, we are expecting to present topline results in the second half of 2020. Interim results from patients with other FGFR2 genetic aberrations, who are included in the second cohort of this study, are also anticipated in the second half of the year. We are on track with patient enrolment in the urothelial cancer, FIDES-02 derazantinib study and are planning to start the FIDES-03 derazantinib study, in gastric cancer, in the third quarter of 2020. In addition, we are preparing the start of the phase 2 study with our tumor checkpoint controller, lisavanbulin, in patients with brain cancer within the next few months.”

Financial summary

Total revenue in the first half-year 2020 increased to CHF 69.3 million (H1 2019: CHF 63.2 million). Revenue contributions from the two marketed brands Cresemba and Zevtera increased by 17.2% to CHF 62.0 million (H1 2019: CHF 52.9 million), of which CHF 36.5 million (H1 2019: CHF 30.1 million) relate to non-deferred revenue and CHF 25.5 million (H1 2019: CHF 22.8 million) to recognition of deferred revenue. Deferred revenue is recognized for upfront, development and regulatory milestone payments received in prior years from partners. Other revenue amounted to CHF 7.2 million (H1 2019: CHF 10.1 million). This included CHF 6.6 million BARDA reimbursements (H1 2019: CHF 9.9 million), which are offsetting a substantial portion of the ceftobiprole phase 3 development expenses.1 The BARDA reimbursements year-on-year decreased in line with the reduced development expenses after the successful completion of the ceftobiprole phase 3 skin infection study and due to the COVID-19 related slower enrolment into the bacteremia study.

In the first half-year 2020, investments in Basilea’s pipeline resulted in research and development expenses of CHF 43.9 million (H1 2019: CHF 50.8 million). Such expenses were mainly driven by costs for the phase 3 program for ceftobiprole, the costs related to the ongoing preclinical and clinical program for derazantinib and the ongoing pediatric programs for ceftobiprole and isavuconazole.

Selling, general and administrative expenses decreased to CHF 14.4 million (H1 2019: CHF 16.2 million). As a result of increasing sales of products to partners, cost of products sold increased to CHF 13.1 million (H1 2019: CHF 9.4 million).

In the first half-year of 2020, the operating profit amounted to CHF 12.8 million (H1 2019: operating loss of CHF 13.2 million), leading to a net profit of CHF 9.9 million (H1 2019: net loss CHF 15.4 million), which resulted in a basic earnings and diluted earnings per share of CHF 0.92 and CHF 0.91, respectively (H1 2019: basic and diluted loss per share CHF 1.44).

Net cash consumption from operating activities (excluding cash inflow from the sale of the headquarters property) in the first half-year 2020 was reduced by 27% to CHF 33.2 million as compared to CHF 45.4 million in H1 2019. This is a result, on the one hand of the significant increase in cash inflow based on Cresemba and Zevtera performance and, on the other hand, of Basilea’s continued focus on managing its operating expenses by continuously optimizing its investments into its preclinical and clinical portfolio. Combined cash and short- and long-term investments amounted to CHF 144.7 million as of June 30, 2020, compared to CHF 161.0 million as of December 31, 2019.

Key financial figures

(In CHF million, except per share data)H1 2020H1 2019
Product revenue30.525.4
Contract revenue31.527.6
Revenue from R&D services0.20.1
Other revenue7.110.1
Total revenue 69.363.2
Cost of products sold(13.1)(9.4)
Research & development expenses, net(43.9)(50.8)
Selling, general & administrative expenses(14.5)(16.2)
Total cost and operating expenses (71.5)(76.4)
Profit from sale of assets15.0-
Operating profit/(loss)12.8(13.2)
Net profit/(loss)9.9(15.4)
Net cash used in operating activities(33.1)(45.4)
Basic earnings/(loss) per share, in CHF0.92(1.44)
Diluted earnings/(loss) per share, in CHF0.91(1.44)
(In CHF million)June 30, 2020Dec. 31, 2019
Cash and short- and long-term investments144.7161.0

Note: Consolidated figures in conformity with U.S. GAAP; rounding was applied consistently.

The unaudited, condensed consolidated interim financial statements of Basilea Pharmaceutica Ltd. for the first half-year 2020 can be found on the Company’s website at

FY 2020 financial guidance

Basilea provides the following updated financial guidance for full-year 2020 based on an assumed average USD/CHF exchange rate of approximately 0.94 in H2 2020 and a gradual easing of COVID-19 lock-down measures over the remainder of 2020:

  • Revenue contributions from Cresemba and Zevtera, excluding deferred revenue recognized for payments received in prior years, are expected to grow to
    CHF 77-87 million (+12% to +27% y-o-y), reflecting the continued significant
    growth of in-market sales by our partners.
  • Total R&D and SG&A expenses are expected to remain approximately stable. Cost of products sold is expected to increase based on higher product deliveries to partners.
    An anticipated extension of the supply period to Pfizer is expected to positively affect revenue and increase cost of products sold, primarily in 2021.
  • The anticipated operating loss amounts to CHF 5-15 million.
  • Cash and short- and long-term investments are expected to be approximately CHF 150 million at year-end 2020. This represents a significant increase compared to the initial guidance, due to the proceeds from the headquarters property sale and the convertible bond transactions and being partially offset by a temporary increase in working capital, which is anticipated to be reversed in early-2021.
(In CHF million)FY 2020e (updated)FY 2020e (initial)FY 2019a
Cresemba & Zevtera revenue (non-deferred)77-8777-8768.7
Cresemba & Zevtera revenue (deferred)333345.6
Other (mostly BARDA reimbursements)17-181820.0
Total revenue128-138128-138134.4
Cost of products sold232518.9
R&D and SG&A135133132.7
Profit from sale of assets1500
Operating loss5-1520-3017.2
Cash and short- and long-term investments

Portfolio – Continued commercial success of our anti-infective brands and important upcoming milestones for our oncology drug candidates

Cresemba in-market sales continue to grow

Cresemba has reached USD 220 million “in-market sales” for the 12 months to the end of March 2020, which is a more than 30% growth year-on-year.2 Our partners have reported a number of additional approvals and launches in territories around the world since the beginning of the year. This includes launches in key markets in Asia Pacific and approval in Russia. These triggered commercial and regulatory milestone payments of approximately CHF 6 million from Pfizer to Basilea. To date, Cresemba has been launched in 45 countries and marketing application processes have been initiated in a number of additional countries, including in China, where the Marketing Authorization Application for mucormycosis was recently accepted for regulatory review by the health authority. We therefore remain confident that our partners will have launched Cresemba in 60 countries by the end of 2021.

Zevtera (ceftobiprole) SAB phase 3 study now expanded to enrol more difficult-to-treat patients

The U.S. Food and Drug Administration (FDA) approved the amendment of the protocol for the phase 3 study ERADICATE, which is conducted in patients with Staphylococcus aureus bacteremia (SAB).3 This amendment extends the maximum treatment duration from four, to now up to six weeks, which allows for the inclusion of patients with more difficult-to-treat infections, including those with complications such as osteomyelitis and epidural or cerebral abscess. We expect that the recruitment of the ERADICATE study can be completed in H2 2021. If the study is positive, as reported for the TARGET phase 3 study last year, which evaluated ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections, Basilea plans to submit a New Drug Application (NDA) to the FDA.4 As ceftobiprole was designated a Qualified Infectious Disease Product (QIDP) by the FDA for these indications, if approved, ceftobiprole will be eligible to receive ten years of market exclusivity in the U.S. from the date of approval.

Key oncology clinical studies with derazantinib and lisavanbulin remain on track

In July, we announced that the patient enrolment into the first cohort of the FIDES-01 study with the FRGR kinase inhibitor, derazantinib, has been completed.5 This first cohort enroled patients with advanced intrahepatic cholangiocarcinoma (iCCA), a type of bile duct cancer, whose tumors expressed fusions of the FGFR2 gene, a genetic aberration which has previously been identified as driving this type of cancer. A second cohort, which enrols iCCA patients with other FGFR2 genetic aberrations, namely mutations and amplifications, is ongoing with interim results expected during H2 2020. The results from the second cohort will support defining the full therapeutic potential of derazantinib in iCCA and potentially further strengthen the differentiation of derazantinib from other FGFR kinase inhibitors. In addition, the clinical development program for derazantinib includes two further Phase 1b/2 studies, the ongoing FIDES-02 in patients with urothelial cancer and the planned FIDES-03, in patients with advanced gastric cancer, which is expected to start in Q3 2020.6 In FIDES-02 and FIDES-03, we are not only exploring derazantinib as a single agent, but also in combination with an immuno-oncology drug, atezolizumab (Tecentriq®), with the rationale that derazantinib may enhance the response to immuno-oncology treatment.7

In 2019, initial results of a phase 1 study with daily oral lisavanbulin in patients with glioblastoma multiforme (GBM), the most common type of primary brain cancer and one of the most lethal types of cancer, have been reported.8 These results showed clinical activity of lisavanbulin in GBM with one exceptional, long-lasting responder, whose brain tumor tissue displayed strong expression of the protein EB1. Full results of the study as well as data on the potential utility of EB1 as a response-predictive biomarker for lisavanbulin have been accepted for presentation at this year’s annual congress of the European Society of Medical Oncology (ESMO) which is taking place in a virtual format in September 2020. Based on the results of this and other studies, we have decided to progress lisavanbulin to the next clinical stage and are preparing a biomarker-driven phase 2 study with lisavanbulin in patients with GBM. The start of the study is anticipated in the next few months. We expect interim results for this study in H1 2021 and top line results in H2 2021. This approach allows us to efficiently test our hypothesis that lisavanbulin can be developed in a targeted patient population, initially in GBM and then potentially in other tumor types.

Conference call and webcast

Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, August 11, 2020, at 4 p.m. (CEST), to discuss the Company’s financial and operating results.

Via audio webcast with presentation

The live audio webcast of the results presentation can be followed here. Please note that there is no function to ask questions via webcast. For questions, please additionally dial-in via phone (see below).

Via phone

To listen by phone and ask questions, please use the dial-in details below. To ensure prompt access, please call approximately five minutes prior to the scheduled start of the call.

+41 (0) 58 310 5000     (Europe and RoW)
+1 (1) 866 291 4166     (USA)
+44 (0) 207 107 0613       (U.K.)


The webcast, along with presentation will be available online shortly after the event and accessible for three months.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website


This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102

This press release can be downloaded from


  1. The ceftobiprole phase 3 program is funded in part (up to USD 128 million, which is approximately 70% of the total estimated program costs) with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201600002C.
  2. IQVIA, March 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  3. ERADICATE study: identifier NCT03138733
  4. TARGET study: identifier NCT03137173
  5. FIDES-01 study: identifier NCT03230318
  6. FIDES-02 study: identifier NCT04045613
  7. Tecentriq® is a registered trademark of Hoffmann-La Roche Ltd.
  8. identifier NCT02490800 


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Aino Health AB (publ): Aino Health ingår samarbete med LifeComp27.10.2020 08:30:00 CETPressemelding

Stockholm 27 oktober 2020: Aino Health meddelar idag att de har ingått ett samarbete med LifeComp. I det nya samarbetet kommer LifeComp att addera kundnytta till Aino Healths plattform i form av förebyggande hälsoanalys och aktiviteter. Bolagen avser även att samverka i försäljningsarbetet. Lifecomp erbjuder personlig algoritmbaserad hälsoanalys, vilket blir ett bra komplement till Ainos SaaS-lösning HealthManager, och stöttande tjänster, inom health management. I och med samarbetet kommer både Aino och Lifecomp att kunna erbjuda sina kunder ett bredare sortiment av tjänster. “Aino Health erbjuder en brilliant plattform – som gör livet betydligt enklare för ett bolags HR-avdelning såväl som för dess chefer, och som passar mycket väl ihop med LifeComps Hälsoanalys.” Fredrik Kjällander, CEO LifeComp. “Jag är mycket glad, att genom LifeComp, kunna addera nyttan av marknadens sannolikt mest avancerade algoritmbaserade hälsoanalys i kombination med olika fysiska tester till våra kunder” säg

Statkraft AS: Offentliggjøring av resultater for tredje kvartal 202026.10.2020 11:25:36 CETPressemelding

Statkraft offentliggjør resultater for tredje kvartal 2020 torsdag 29. oktober 2020 klokken 08.00. Materialet vil være tilgjengelig på Statkrafts internettsider og på Oslo Børs Direkte webcast Kl. 09.00: Statkraft presenterer resultatene på webcast som overføres direkte på Presentasjonen holdes på engelsk. Kontaktperson: Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-post: Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Nokia wins 5G deal with Finnish Shared Network (SYV)26.10.2020 10:00:00 CETPress release

Press Release Nokia wins 5G deal with Finnish Shared Network (SYV) Nokia has been selected as a supplier for SYV’s radio access network (RAN) equipment and managed services The deal includes the rollout of 5G RAN equipment and modernization of existing 2G, 3G and 4G sites across northern and eastern FinlandThree-year rollout will begin in early 2021 and is planned to be completed by the end of 2023. 26 October 2020 Espoo, Finland – Nokia today announced it has been selected by Finnish Shared Network Ltd (SYV) – a joint operation by DNA Oyj and Telia Finland Oyj – as a supplier of 5G radio network equipment including deployment and managed services. The modernized network will enable SYV to provide advanced 5G services in a cost-efficient manner across northern and eastern parts of Finland. The deal will see Nokia replace SYV’s current radio access network equipment, offer digital deployment for faster time to market, and comprehensive managed services over the course of the three-year

ZetaDisplay invites to presentation of the interim report26.10.2020 09:30:00 CETPress release

Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) invites to an audiocast in connection with the publication of the interim report January – September 2020. The report will be published on 4 November at 08:00 CET and the audiocast is scheduled for 10:00am p CET on the same day. ZetaDisplay invites you to participate via the link The presentation will be held in English by CEO Per Mandorf and CFO Jacob Stjernfält. Malmö, 26 October 2020 For questions, please contact: Per Mandorf, President & CEO Phone +46 704-25 82 34 Jacob Stjernfält, CFO Phone +46 76-8754177 E-mail Daniel Oelker, CCO Phone +46 708-45 80 54 About ZetaDisplay ZetaDisplay acts at the heart of digit

ZetaDisplay bjuder in till presentation av delårsrapporten26.10.2020 09:30:00 CETPressemelding

Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) bjuder in till en audiocast i samband med publiceringen av delårsrapporten januari – september 2020. Rapporten publiceras den 4 november 2020 klockan 08:00 och presentationen sker via en audiocast kl 10:00 samma dag. ZetaDisplay bjuder in till deltagandet via länken Presentationen kommer att hållas på engelska av VD Per Mandorf och CFO Jacob Stjernfält. Malmö, 26 oktober 2020 För vidare information, vänligen kontakta: Per Mandorf, Koncernchef & VD Telefon +46 704-25 82 34 Jacob Stjernfält, CFO Telefon +46 76-8754177 E-mail jacob, Daniel Oelker, CCO Telefon +46 708-45 80 54 Om ZetaDisplay ZetaDisplay driver den digitala t

PETRONAS awards MultiClient programs in Sarawak Basin to seismic consortium26.10.2020 08:50:07 CETPress release

OSLO, NORWAY, October 26, 2020: The seismic consortium comprising PGS, TGS and WesternGeco have been awarded a multi-year contract by PETRONAS through competitive bidding to acquire and process up to 105,000 square kilometers of multi-sensor MultiClient 3D data in the Sarawak Basin, offshore Malaysia. This contract award follows an ongoing campaign by the consortium in the Sabah offshore region of Malaysia, awarded in 2016, in which over 50,000 square kilometers of high-quality 3D seismic data have been acquired and licensed to the oil and gas industry to support Malaysia license round and exploration activity. The Sarawak award will enable the consortium to position itself in Malaysian seismic exploration and allow for a multi-phase program to promote exploration efforts in the prolific Sarawak East Natuna Basin (Deepwater North Luconia and West Luconia Province). “We are very pleased to have received this good news from PETRONAS through Malaysia Petroleum Management,” said Nathan Oli